EnCor Biotechnology
Recombinant Human Vimentin Cat# Prot-r-Vim
Description
We designed a cDNA to encode human vimentin optimized or expression in E. coli which was inserted into the pET30a(+) vector. This vector adds an N-terminal His-tag and some other vector sequence which can be removed with thrombin or enterokinase proteases. The His-tag allows convenient purification using Nickel affinity chromatography. Sensitive ELISA, MSD, Luminex and Simoa assays for vimentin have been developed and are widely used in research and clinical contexts. This recombinant protein can be used as a convenient protein standard for such assays. The product data and MSDS information can be downloaded from the “Data Sheets” tab below.
Add a short description for this tabbed section
Name: | Vimentin protein, Cat# Prot-r-Vim |
HGNC Name: | VIM |
UniProt: | P08670 |
Molecular Weight: | 54kDa by SDS-PAGE plus about 5kDa tag sequence |
Host: | E. coli |
RRID: | NA |
Format: | 1mg/mL in 6M Urea, 10mM phosphate pH=7.5 |
Applications: | Protein standard for ELISA, MSD, Luminex and Simoa assays, also immunogen for antibody production |
Storage: | Stable at 4°C for several months. For longer term store at -20°C or lower |
Vimentin is a member of the intermediate or 10nm family of proteins, which are abundant structural components of most eukaryotic cells. Vimentin is found in most cell lines grown in tissue culture (1). In adult animals vimentin is expressed in mesenchymal cells, lymphocytes, some types of glia, endothelial cells and many other cell types particularly early in development (2). Several recent studies suggest that vimentin may be detected in blood in increased levels in association with various disease processes, so that detection of serum or plasma vimentin might be useful as a diagnostic or prognostic biomarker of damage or disease (e.g. 3,4).
1. Franke WW, et al. Different intermediate-sized filaments distinguished by immunofluorescence microscopy. PNAS 75:5034–8 (1978).
2. Muller M, et al. Dominant cataract formation in association with a vimentin assembly disrupting mutation. Hum. Molec. Genet. 18:1052-7 (2009).
3. Chaw SY, et al. Epithelial to mesenchymal transition (EMT) biomarkers – E-cadherin, beta-catenin, APC and Vimentin – in oral squamous cell carcinogenesis and transformation Oral Oncol. 48:997-1006 (2012).
4. Toiyama Y, et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 34:2548-57 (2013).
Add a short description for this tabbed section